Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.60 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.58 |
| ▸ | CCR5 | P51681 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | CFD | P00746 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | F11 | P03951 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548139 | 0.93 | USP28 (0.54) | USP28USP25HTTPTGER1CCR5 | |
| SCHEMBL4767265 | 0.90 | USP28 (0.59) | USP28USP25HTTPTGER1CCR5 | |
| SCHEMBL15820919 | 0.86 | CCR5 (0.60) | USP28USP25HTTPTGER1CCR5 | |
| SCHEMBL8733926 | 0.86 | HTR2C (0.50) | USP28USP25HTTPTGER1ALDH1A1 | |
| SCHEMBL16294058 | 0.86 | PTGER1 (0.64) | USP28USP25HTTPTGER1CCR5 | |
| SCHEMBL2537375 | 0.85 | FFAR1 (0.52) | USP28USP25PTGER1CCR5ALDH1A1 | |
| SCHEMBL9077270 | 0.85 | PTGDR2 (0.49) | USP28USP25HTTPTGER1ALDH1A1 | |
| SCHEMBL2538737 | 0.84 | PTGER1 (0.61) | PTGER1CCR5RAB9ACYP1A2LMNA | |
| SCHEMBL16396653 | 0.84 | CFD (0.74) | USP28USP25PTGER1CCR5PTGER4 | |
| SCHEMBL7823412 | 0.84 | PTGER1 (0.54) | PTGER1PTGER4PTGER3PTGER2CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| WO-2009125606-A1 | PAI-1 INHIBITOR | 株式会社医薬分子設計研究所 (JP) | 2009-10-15 | — | — | WO | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-6787562-B2 | ANALGESICS; OSTEOPOROSIS | ZENECA LTD. (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20040138309-A1 | Novel substituted benzoic acid amides, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004013128-A1 | NOVEL SUBSTITUTED BENZAMIDES PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM (DE) | 2004-02-12 | — | — | WO | disclosed |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | SYNGENTA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6057345-A | ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF | ZENECA LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| US-5834468-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES | ZENECA LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
| US-5495046-A | PSYCHOLOGICAL DISORDERS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1996-02-27 | — | — | US | disclosed |
| EP-0641766-A1 | ALKOXYPHENYLALKYLAMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138309-A1 | Novel substituted benzoic acid amides, their preparation and their use as pharmaceutical compositions | F11, F12, SERPINC1 | USP28 4124/4885USP25 2725/4885HTT 1590/4885 |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | PTGER1, PTGDR, PTGER2 | USP28 4223/4885USP25 4395/4885HTT 4559/4885 |
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | USP28 3233/4885USP25 2259/4885HTT 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.